If you are unable to access ON24 click here.
Dr. Khoo, Clinical Oncologist, The Royal Marsden, London and Dr. Blacksburg, VP, Chief Medical Officer (AMS), Accuray during this webinar will discuss the highlights from the September prostate webinar series and share their expert perspective on the future advances in prostate Stereotactic Body Radiotherapy (SBRT) and hypofractionated treatments.
Vincent Khoo, MB BS, FRACR, FRCR, M.D., Clinical Oncologist, The Royal Marsden, London, UK
Vincent Khoo is a Clinical Oncologist at The Royal Marsden Hospital, Honorary Oncologist at St George’s Hospital, an Honorary Reader at the Institute of Cancer Research, University of London, Adjunct Professor, Department of Medical Imaging and Radiation Sciences, Monash University, and Honorary Associate Professor, Department of Medicine, Melbourne University, and Austin Health, Australia. He specializes in urological cancers, with interests in technical radiotherapy from stereotactic to image-guided intensity-modulated RT; adaptive RT; brachytherapy; multimodality imaging; systemic therapy and clinical trials (phase I – IV studies); as well as evaluation of genetic, and bio-prognostic markers. He is a member of several national and international research study groups, scientific committees, and advisory and editorial boards including the UK NCRI Clinical Study Group, Genetic Prostate Groups, ESTRO, ESMO, and ECCO scientific committees. He has published over 240 papers.
Seth Blacksburg, M.D., VP, Chief Medical Officer, Accuray Americas
Dr. Blacksburg is a board-certified radiation oncologist who earned a master of business administration degree while concurrently completing his medical studies. He is highly skilled in all facets of radiation oncology, with expertise in stereotactic body radiotherapy (SBRT) and radiosurgery for prostate cancer, breast cancer, CNS cancers, and other tumor sites, LDR and HDR brachytherapy, and integrating radiation with immunotherapy.
He serves as VP, CMO of the Americas at Accuray. Prior to joining Accuray, Dr. Blacksburg was chairman of radiation medicine at Lenox Hill Hospital, a part of Northwell Health, the largest private employer in New York (state). Dr. Blacksburg was responsible for the clinical oversight and strategic development of the department. He also served as a key member of the hospital’s cancer committee, medical board and national accreditation programs for breast and rectal cancers. During Dr. Blacksburg’s tenure with the Lenox Hill cancer program, the cancer program achieved Commission on Cancer (CoC) accreditation and the department patient volume increased significantly.
Prior to joining Lenox Hill, Dr. Blacksburg served as associate director of radiation oncology and medical director of NYCyberKnife Center at NYU Winthrop Hospital. In addition, he held the academic title of clinical associate professor at the NYU Long Island School of Medicine. He was also previously a radiation oncologist at the Icahn School of Medicine at Mount Sinai Hospital. Throughout his career, Dr. Blacksburg has been the principal and senior researcher in a wide array of clinical investigations, which have primarily focused on stereotactic radiation therapy and treatment outcomes for genitourinary cancers. As a highly sought-after expert within his field, he has been invited to lecture, teach and present at numerous national and international conferences.
Dr. Blacksburg is affiliated with the American Society for Radiation Oncology and the American Board of Radiology. He also serves as a reviewer for several distinguished academic journals. After graduating summa cum laude from Tufts University, Dr. Blacksburg concurrently pursued a medical degree from the Duke University School of Medicine, where he served as class president, and a Master of Business Administration degree with a concentration in health sector management from the Duke University Fuqua School of Business.
His post-graduate training included an internship in internal medicine at New York University/Bellevue Hospital and a residency in radiation oncology at the Icahn School of Medicine at Mount Sinai, where he served as chief resident for two years. He stayed on as faculty at Mount Sinai where he was the first radiation oncologist selected into the Greater New York Hospital Association/United Hospital Fund clinical quality fellowship.
